Hemab Therapeutics (NASDAQ:COAG) Issues Earnings Results

Hemab Therapeutics (NASDAQ:COAG) released its quarterly earnings results on Tuesday. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17), FiscalAI reports.

Hemab Therapeutics Price Performance

COAG stock traded down $0.07 during midday trading on Tuesday, reaching $49.80. 20,729 shares of the company’s stock traded hands, compared to its average volume of 320,414. The stock’s 50-day simple moving average is $36.98. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $53.61. The company has a market cap of $2.33 billion and a P/E ratio of -2.08.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Evercore initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $55.00 target price (up from $42.00) on shares of Hemab Therapeutics in a report on Monday, July 13th. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target for the company. Finally, Jefferies Financial Group lifted their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Hemab Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.00.

Insider Transactions at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of Hemab Therapeutics stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the transaction, the insider owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. This trade represents a 0.96% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have purchased a total of 72,467 shares of company stock valued at $1,809,595 over the last three months.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.